Janney Capital Maintains Buy On Raptor Pharmaceutical, Sees 34% Upside
In a research note released this morning, Janney Capital analyst Kimberly Lee maintained a Buy rating on Raptor Pharmaceutical (RPTP) with a $17 price target, ahead of the company’s upcoming revenue report.
Lee wrote, “We forecast Procysbi revenue of $14.1 million compared to consensus of $14.6 million. We do not expect any changes to this year’s financial guidance. On the earnings call, we anticipate an update on EU reimbursement and on the pipeline, in particular, feedback from the FDA regarding the development and regulatory pathway in Huntington’s disease (HD)”.
According to TipRanks.com, which measures analysts and bloggers success rate based on how their calls perform, analyst Kimberly Lee currently has a one-year average return of 12.0% and a 53% success rate. Lee is ranked #970 out of 3213 analysts.